Bradford Lee
Ophthalmology · Honolulu, HINPI 1710113352
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $3,412 of the $5,212 with a category attached, or 65.5%. Amgen accounts for 67.0% of it on its own, with 16 other manufacturers making up the rest. Reporting peaked in 2023 at $2,210 and has fallen 79.0% since, to $464 in 2025.
Across 72 payments — averaging $72.39 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$3K
- AbbVie$369
- Alcon$322
- Genentech USA, Inc.$309
- Dompe US, Inc.$157
- Bausch & Lomb, A Division Of Bausch Health US, LLC$122
- plus $437 from 11 others
What the payments were for
- Consulting fees$3006%
- Speaking & faculty fees$1,50029%
- Food & beverage$3,41265%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen(2 entities) | 40 | $3,494 |
| AbbVie(2 entities) | 4 | $369 |
| Alcon | 3 | $322 |
| Genentech USA, Inc. | 3 | $309 |
| Dompe US, Inc. | 2 | $157 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 1 | $122 |
| Sun Pharmaceutical Industries Inc. | 3 | $67 |
| Novartis | 3 | $62 |
| Merz North America, Inc. | 2 | $52 |
| Galderma Laboratories, L.p. | 2 | $46 |
| Merz Pharmaceuticals, LLC | 2 | $39 |
| Aerie Pharmaceuticals, Inc. | 2 | $39 |
| Glaukos Corporation | 1 | $37 |
| Solta Medical, A Division Of Bausch Health US, LLC | 1 | $32 |
| Tarsus Pharmaceuticals, Inc. | 1 | $21 |
| Acelrx Pharmaceuticals, Inc. | 1 | $20 |
| Oyster Point Pharma, Inc. | 1 | $20 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$5,212 in reported general payments places this provider in the 65th percentile of 120 ophthalmology providers in Hawaii.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha | 336 | $3,757 |
| ErythromycinErythromycin Base | 30 | $267 |
| Doxycycline Hyclate | 12 | $69 |
Paid to pharmacies, not to this prescriber.
Other ophthalmology in Honolulu
- Neda NikpoorHonolulu$293K
- Carlton YuenHonolulu$175K
- Alan FaulknerHonolulu$135K
- Michael BennettHonolulu$108K
- Jeffrey PetersonHonolulu$77K
- Rupa WongHonolulu$72K
- Jon PortisHonolulu$20K
- Tyrie JenkinsHonolulu$19K
- John OlkowskiHonolulu$15K
- Claudia HootenHonolulu$14K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.